Through 2021, the Launch of Emerging Agents Will Boost Major-Market Sales of Therapies to Pulmonary Arterial Hypertension to $3.5 Billion

Through 2021, the Launch of Emerging Agents Will Boost Major-Market Sales of Therapies to Pulmonary Arterial Hypertension to $3.5 Billion

Christopher Comfort, 781-993-2597

Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite the fact that several leading brands are near the end of their patent exclusivity, the launch of novel agents over the next decade will more than compensate for lost revenue in the pulmonary arterial hypertension (PAH) drug market. Through 2021, the launch of emerging agents will boost major-market sales of therapies to treat PAH to $3.5 billion in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The Pharmacor report entitled finds that the launch and uptake of Actelion/Nippon Shinyaku’s macitentan and selexipag and Bayer Healthcare’s riociguat will drive combined sales of nearly $1.2 billion in 2021 for these agents.

Leading brands that will lose market exclusivity by 2021 include the endothelin receptor antagonists bosentan (Actelion’s Tracleer) and ambrisentan (Gilead’s Letairis, GlaxoSmithKline’s Volibris) and the phosphodiesterase-5 (PDE-5) inhibitors sildenafil (Pfizer’s Revatio) and tadalafil (United Therapeutics/Eli Lilly/Nippon Shinyaku’s Adcirca).

“Anticipated generic erosion will contribute to a reduction in sales of these brands of more than $1 billion between 2011 and 2021,” said Decision Resources Analyst Matthew Scutcher, Ph.D.

The report also finds that results of several major trials, including AMBITION, COMPASS-2 and COMPASS-3, are expected to engender greater consensus among physicians regarding the choice of first- and subsequent-line therapies and may trigger changes in international guidelines for PAH management.

Decision Resources () is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at .

Suggested Articles

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

Durect’s share price fell 12% after half of the panel of painkiller experts recommended against approving Posimir.

China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite.